1. Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria.
- Author
-
Zhuang, Zhijun, Wan, Dawei, Ding, Jun, He, Shijie, Zhang, Qian, Wang, Xiaomei, Yuan, Ying, Lu, Yu, Z. Ding, Charles, Lynch, Anthony Simon, M. Upton, Anna, B. Cooper, Christopher, A. Denny, William, Ma, Zhenkun, Wakelin, Larry, and Gemma, Sandra
- Subjects
MULTIDRUG-resistant tuberculosis ,ANAEROBIC bacteria ,MYCOBACTERIUM tuberculosis ,BACTERIAL diseases ,ANTI-infective agents ,MYCOBACTERIA ,COMMUNICABLE diseases - Abstract
The introductions of the bicyclic 4-nitroimidazole and the oxazolidinone classes of antimicrobial agents represented the most significant advancements in the infectious disease area during the past two decades. Pretomanid, a bicyclic 4-nitroimidazole, and linezolid, an oxazolidinone, are also part of a combination regimen approved recently by the US Food and Drug Administration for the treatment of pulmonary, extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) Mycobacterium tuberculosis (TB). To identify new antimicrobial agents with reduced propensity for the development of resistance, a series of dual-acting nitroimidazole-oxazolidinone conjugates were designed, synthesized and evaluated for their antimicrobial activity. Compounds in this conjugate series have shown synergistic activity against a panel of anaerobic bacteria, including those responsible for serious bacterial infections. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF